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 ABSTRACT
Inflammatory bowel disease and its various treatments may affect the kidney in several ways. Tubuloin-
tersticial nephritis is a rare but serious complication of longer-term mesalazine use. There are few cases 
reported in the literature. We report the first two cases of mesalazine-induced tubulointersticial nephritis, 
recently diagnosed in our department. The first one refers to a patient with ulcerous colitis and the second 
one to a patient with Crohn’s disease. Then the authors present a review of literature about the renal 
involvement in the inflammatory bowel disease. New cases of mesalazine nephrotoxicity should be reported 
to allow more accurate incidence estimation of this serious adverse effect. Routine monitoring of renal 
function is simple, inexpensive and allows an early diagnosis of this complication.
Key-Words: Inflammatory bowel disease; kidney disease; mesalazine; tubulointersticial nephritis.
 RESUMO
A doença inflamatória intestinal e as terapêuticas que lhe estão associadas podem afetar o rim de várias 
formas. A nefrite tubulointersticial é uma complicação rara, mas potencialmente grave inerente à terapêutica 
com mesalazina. Há alguns casos descritos na literatura. Os autores descrevem os dois primeiros casos de 
nefrite tubulointersticial associados ao uso de mesalazina, recentemente diagnosticados no nosso Serviço; 
um deles num doente com colite ulcerosa, outro num doente com doença de Crohn. Apresentam uma 
revisão da literatura sobre o atingimento renal na doença inflamatória intestinal. Os casos de nefrotoxicidade 
associada à mesalazina devem continuar a ser descritos para permitir estabelecer uma incidência mais 
precisa desde efeito adverso. A monitorização da função renal durante o tratamento é simples, barata e 
pode ajudar a diagnosticar precocemente esta complicação.
Palavras-Chave: Doença inflamatória intestinal; doença renal; mesalazina; nefrite tubulointersticial.
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 INTRODUCTION
Inflammatory bowel disease (IBD) is associated 
with a large spectrum of kidney disease. The kidney 
may be an extra-intestinal target of IBD. It could be 
affected by the secondary complications of bowel 
inflammation, such as stones and amyloidosis; there 
are some reported associations of glomerular dis-
ease1. On the other hand, some drugs used in its 
treatment, including mesalazine, may be associated 
with tubulointersticial renal disease1-3. Acute and 
chronic interstitial nephritis are rare but serious com-
plications of longer-term mesalazine use4. There are 
some reports in the literature1,5-7. This adverse drug 
reaction is likely idiosyncratic. The clinical presenta-
tion is usually non-speciﬁc and more frequent in 
men than in women8,9.
We report two cases of tubulointersticial nephritis 
(TIN) associated with mesalazine treatment, recently 
diagnosed in our department. The first refers to a 
patient with ulcerous colitis (UC) and the second 
one to a patient with Crohn’s disease (CD). Then the 
authors present a literature review about renal 
involvement in IBD.
 CASE REPORTS
 Case 1
A man with a past history of controlled hyperten-
sion and healed prostatic neoplasm had a diagnosis 
of UC at 59 years old (in 2011). At this time, he had 
1.05 mg/dl serum creatinine and no urinalysis abnor-
malities, namely proteinuria, leukocyturia or eryth-
rocyturia. Due to disease activity, he began treatment 
with oral mesalazine (1600 mg/day) and prednisolone. 
One year later, he had a 1.9 mg/dl serum creatinine. 
At that moment, the UC was in activity and mesala-
zine dose was increased (1.6 to 3.6 g/day). Three 
months later, the serum analysis showed an increase 
in creatinine (2.1 mg/dl) and urinalysis showed pro-
teinuria (100 mg/dl), leukocyturia (25-50 WBC/field) 
and erythrocyturia (25-50 RBC/field). At Nephrology 
evaluation, IBD was in clinical remission. The patient 
had no symptoms and no abnormalities on physical 
examination. Initial laboratory results were: normal 
haemoglobin, normal leucocyte, eosinophils and 
platelets count; blood urea nitrogen 80 mg/dl, serum 
creatinine 2.1mg/dl; normal serum sodium, potas-
sium, calcium and phosphorus. Urinalysis revealed: 
an albumin/creatinine ratio 1420 mg/g, a protein-
creatinine ratio 1.5g/g, erythrocyturia and leukocytu-
ria. The urine culture was negative. Serology revealed 
normal C3, C4, IgG, IgM, IgG; negative anti-nuclear 
antibody (ANA); positive anti-saccharomyces cerevi-
siae (ASCA) test. Renal ultrasound did not reveal 
any hydronephrosis, nephrolithiasis or cortical atro-
phy; both kidneys were of normal size. Kidney biopsy 
showed an acute interstitial nephritis with linfomono-
nuclear cells and a granulomatous reaction without 
central necrosis (Figs. 1 and 2). The vessels were 
normal; there was 40% fibrosis and 20% tubular 
atrophy. Immunofluorescence with auto-antibodies 
to albumin, C3, C4, C1q, IgA, IgM and IgG was posi-
tive to mesangial and peripheral deposits for C3 and 
linear IgA(+).
Mesalazine was discontinued and azathioprine was 
introduced (2 mg/Kg) in combination with predniso-
lone (5mg/day). Two months later, serum creatinine 
decreased to 1.5 mg/dl and urinalysis revealed no 
white blood cells/field and 2-5 red blood cells/field; 
proteinuria/creatinine ratio decreased to 0.3 g/g.
 Case 2
A man with Crohn’s disease and no other relevant 
medical history was sent to Nephrology consultation 
Figure 1
Acute interstitial nephritis. The granulomata (black arrow) involving and 
destroying the tubules. Necrotizing features were not identified (H&E x100).
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for chronic kidney disease. Inflammatory bowel dis-
ease had been diagnosed when he was 35 years old 
(in 2009). At that moment, he had a serum creatinine 
of 0.8mg/dl, with no abnormalities in urinalysis. He 
started oral mesalazine (4g/day) and prednisolone 
(60 mg/day) with a gradual decrease of doses and 
clinical remission. One year later he had 1.48 mg/dl 
serum creatinine. After two years, he had 1.80 mg/
dl serum creatinine and leukocyturia (25-50 WBC/
field) in urinalysis. Mesalazine was discontinued and 
he started azathioprine (AZA) (1mg – 2mg/kg/day) 
with poor control of IBD activity and need to increase 
the corticosteroids (CT) dose (1mg/kg/day) with a 
gradual decrease and clinical remission. At Nephrol-
ogy evaluation, the patient had only gastro-intestinal 
symptoms (abdominal discomfort and diarrhoea). 
Abdomen examination revealed increased bowel 
sounds and diffuse tenderness to palpation with no 
other abnormalities. Initial laboratory results were: 
haemoglobin 13g/dl; normal leucocyte, eosinophils 
and platelets count; blood urea nitrogen 120, serum 
creatinine 2,6mg/dl and a normal serum sodium, 
potassium, calcium and phosphorus. Urinalysis 
revealed: albumin, red blood cells (10 RBC/field) and 
white blood cells (25-50 WBC/field). The urine culture 
was negative. Serology revealed normal C3, C4, IgG, 
IgM, IgG; negative anti-nuclear antibody (ANA); posi-
tive ASCA test. Renal ultrasound was normal. Kidney 
biopsy showed glomerulosclerosis (30%) and a 
marked interstitial inflammatory infiltrate with eosino-
phils in 30% of cortex extension and mononuclear 
cells (Fig. 3). Vessels were normal. There was 50% 
cortical atrophy (Fig. 4). Immunofluorescence with 
auto-antibodies to albumin, C3, C4, C1q, IgA, IgM 
and IgG was negative.
Three months after stopping mesalazine, serum 
creatinine decreased to 1.5 mg/dl and urinalysis 
revealed no white or red blood cells. Six months 
after treatment with AZA and lower doses of pred-
nisolone (5 mg/day), the IBD became active. AZA 
was increased to 2 mg/kg/day and CT to 1 mg/kg/
Figure 3
Marked interstitial inflammatory infiltrate with numerous eosinophil 
and mononuclear cells, most of them lymphocytes (H&E x400).
 
Figure 2
The granulomata with multinucleated giant cell (black arrow) (H&E x400).
 
Figure 4
Mixed inflammatory cells infiltrating the renal cortex. Glomerulosclerosis 
can be observed. Tubular atrophy is remarkable (H&E x100).
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day with clinical remission. AZA was stopped two 
months later due to pancytopenia. The patient was 
proposed for further treatment with anti-TNF due to 
refractory IBD.
 DISCUSSION
Aminosalicylates compounds are widely used in 
acute phase and remission maintenance therapy of 
IBD10. Mesalazine also known as 5-aminosalicylic 
acid (5-ASA), is a derivative of salicylic acid and it 
is the active moiety of sulfasalazine (without the 
adverse effects attributed to the latter one). A number 
of reports have linked oral mesalazine therapy to 
tubulointersticial nephritis. Although this association 
is currently well established there are no guidelines 
for monitoring renal function in patients who are 
receiving this treatment11.
The first reports were published in 1989, and in 
1990 the Committee on Safety of Medicines (CSM) 
issued a warning of nephrotoxic reactions to mesala-
zine. From 1985 to 1997, the CSM had received 35 
reports implicating the drug in interstitial nephritis. 
In recent editions of nephrology textbooks, mesala-
zine is one of the drugs that could be associated 
with acute and chronic interstitial nephritis9,12,13. 
The true incidence of this problem is not really 
known. Primas et al. showed that renal impairment, 
defined as any increase in serum creatinine, may 
occur in up to one in 100 patients treated with this 
drug14. The incidence of clinically significant inter-
stitial nephritis was estimated to be less than one 
in every 500 patients treated, when serum creatinine 
is monitored regularly. In a larger study of 223 out-
patients with IBD, Schreiber et al. found an increased 
prevalence of tubular proteinuria in patients who 
were receiving high dosages of 5-ASA11. All reports 
of interstitial nephritis in IBD patients are associated 
with drugs used in its treatment9.
The nephrotoxicity associated with mesalazine 
takes the form of an acute or an indolent chronic 
and progressive interstitial nephritis. It can be severe 
and lead to chronic kidney disease14,15. The develop-
ment of tubulointersticial nephritis is independent 
of treatment duration. Fifty per cent of patients pres-
ent within the first 12 months of starting therapy but 
some are diagnosed within 5 years after beginning 
treatment1. It has been suggested that undercurrent 
steroid therapy used in the IBD treatment may delay 
presentation.
Signs and symptoms are scanty and non-specific. 
Patients may be asymptomatic, such as those who 
presented. A minority of patients have systemic 
symptoms like fever, myalgia, anorexia and weight 
loss16. An increase in serum creatinine is a late event 
but may be the first evidence of nephrotoxicity. 
Reagent strip urinalysis can be normal, or positive 
to blood and protein. Proteinuria can be mild to 
heavy and can be influenced by IBD activity. Sterile 
pyuria may be present. Eosinophilia has been record-
ed but it is not a specific finding16-18.
The pathogenic basis of mesalazine associated 
interstitial nephritis is not completely known. In the 
acute stage of the disease, there is a mixed inflam-
matory cell infiltrate composed of B and T lympho-
cytes and macrophages, with interstitial oedema, 
which is comparable to that seen in renal allograft 
acute cellular rejection. It has been suggested that 
this represents a delayed cell-mediated hypersensi-
tivity response16-20. Only a minority of patients mani-
fest a systemic type-I hypersensitivity reaction with 
fever and eosinophilia8.
In the chronic stage, the cellular infiltrate is accom-
panied by interstitial fibrosis and tubular atrophy, 
as it happened in our second case. The extent of 
these hallmarks means an irreversible renal impair-
ment and is predictive of progression to chronic 
renal failure21.
Mesalazine is structurally related to salicylic acid; 
salicylates inhibit the synthesis of intra-renal prosta-
glandins, which are vasoactive mediators of intra-renal 
blood flow, uncouple oxidative phosphorylation in 
mitochondria and inhibit the pentose phosphate shunt 
rendering the kidney susceptible to oxidative dam-
age22-25. All of these effects cause a disturbance in 
intra-renal blood flow and promote local tissue hypox-
ia. Direct tubular toxicity in addition to tissue hypoxia 
is also suggested20,21. After reperfusion injury, there 
is an inflammatory response that may contribute to 
chronic inflammation and interstitial fibrosis23-26.
Due to the small number of cases described and 
the inability to determine the degree of systemic 
absorption, is impossible to say if nephrotoxicity is 
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dose-related. Tubulointersticial nephritis has been 
reported in patients taking doses of mesalazine as 
low as 400 mg/day. The systemic bioavailability is 
determined by the route of administration and by 
the location and extent of the IBD. Systemic absorp-
tion of rectal mesalazine is approximately 50% of 
oral mesalazine; there is no report of significant 
nephrotoxicity in patients using only rectal formula-
tion; the nephrotoxicity could be an idiosyncratic 
effect20,24.
In the Dutch Pentasa Study, over 150 subjects 
were screened prospectively for renal toxicity. They 
were randomized to receive two dosages of oral 
slow-release mesalazine (1.5 vs. 3.0 g per day), and 
followed-up for 12 months. There were no differences 
in toxicity or compliance rate between the high and 
low dose groups. Two patients (1.3%) developed 
modest, reversible renal impairment, but only one 
of them had biopsy proven interstitial nephritis21.
Mesalazine should be withdrawn when the renal 
impairment is not explained by other factors. A renal 
biopsy provides diagnostic and prognostic informa-
tion. It is indicated in subjects with impaired renal 
function that is not explained by other factors, in 
which renal function does not recover to baseline 
following withdrawal of the drug, or in those who 
present with atypical features such as nephrotic range 
proteinuria, which may suggest an alternative diag-
nosis. The response to drug withdrawal is variable. 
It leads to recovery of renal function in 85% of cases 
where the diagnosis is made within 10 months of 
starting treatment. When the diagnosis is delayed 
beyond 18 months from the start of treatment only 
one-third of cases show some recovery of renal func-
tion and this is usually only partial20-23. Active chronic 
tubulointersticial nephritis was described in biopsies 
from patients in whom mesalazine has been with-
drawn several months prior to biopsy19,22,26.
Steroids and azathioprine have been used for IBD 
treatment with a good response, but this depends 
of level on the established chronicity lesions in renal 
biopsy. Nevertheless, a trial of high dose steroid (1 
mg/day/kg, maximum 60 mg/day for up to 3 months) 
is recommended in patients whose renal function 
does not respond to drug withdrawal alone. This 
may be preceded by pulsed intravenous methylpred-
nisolone in severe cases (0.5 to 1 g on three suc-
cessive days).
Both our patients had improvement in renal function 
after discontinuation of the drug and none of them 
made  an intensive course of corticosteroid therapy. In 
both cases, the low-dose of corticosteroids may have 
contributed to the improvement of the renal function.
  Other manifestations of renal disease in patients 
with inflammatory bowel disease (IBD)
Extraintestinal manifestations (EIM) of IBD are 
common. These manifestations can involve nearly 
any organ system – including the renal but also the 
musculoskeletal, dermatologic, hepatopancreatobili-
ary, ocular, and pulmonary systems9. Symptoms of 
renal impairment are not always specific and since 
the underlying bowel disease is preponderant, renal 
function deterioration may be underestimated10.
Renal or urinary complications can occur in 
4%-23% of patients; the most common manifesta-
tions are kidney stones, enterovesical fistulas and 
ureteral obstruction. Patients with IBD have a 10 to 
100 time higher risk of nephrolithiasis compared with 
the general population. The risk is higher in adults 
than in children and in patients with CD. Kidney 
stones in IBD are composed primarily of calcium 
oxalate or uric acid26.
Fistulas between the gastrointestinal tract and the 
urinary system are uncommon, occuring in 1%-8%; 
they are more common in patients with ileal or ileoce-
cal disease than in patients with colonic disease27.
Morphological changes in the glomeruli – podocyte 
effacement, mesangial deposition of immunoglobulin 
and complement have been well described. There 
are also reported associations with membranous 
glomerulonephritis, rapidly progressive glomerulo-
nephritis, mesangiocapillary glomerulonephritis, IgA 
nephropathy (as in our first case), and thin basement 
membrane disease1,9,26-31. Glomerulonephritis pre-
senting as nephrotic syndrome in patients with IBD 
is rare16. Tubular damage was seen in 31% of CD 
and in 23% of UC patients who were not on ASA 
therapy. Granulomatous interstitial nephritis, inter-
stitial nephritis with hyperoxalouria and renal tubular 
acidosis have also been reported32-35.
Secondary amyloidosis (AA amyloidosis) is a rare 
but serious complication that may occur in chronic 
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inflammation diseases, including IBD, mainly long-
standing Crohn’s disease. The reported prevalence 
of secondary amyloidosis in IBD patients varies from 
0.5 to 29% in CD and from 0 to 0.4% in UC with a 
higher prevalence at autopsy16,29.
The majority of patients have renal involvement 
with asymptomatic proteinuria or manifestations of 
nephrotic syndrome. Differential diagnosis of pri-
mary systemic amyloidosis presenting as regional 
enteritis should always be considered. The response 
of IBD-related secondary amyloidosis to treatment 
is variable. It is reported that medical or surgical 
treatment has stabilized or improved renal disease 
but there exist reports suggesting no benefit with 
them30.
There is only a retrospective review study to date 
that examined the histopathology of 83 renal biopsies 
performed in IBD patients. The authors present 45 
and 38 cases CD and UC, respectively. IgA nephropa-
thy was the most common finding (24%), followed 
by interstitial nephritis (19%), arterionephrosclerosis 
(12%), acute tubular injury (8%), proliferative GN 
(7%), and minimal-change disease (5%). Of the 16 
cases of interstitial nephritis, nine (56%) had current 
or recent past exposure to aminosalicylates, including 
all cases of granulomatous interstitial nephritis17.
There are no specific guidelines for surveillance of 
renal function. Frandsen et al. recommend measure-
ment of serum creatinine prior to the start of mesala-
zine treatment and every 6 months thereafter4.
 CONCLUSIONS
These are the first two cases of TIN associated 
with mesalazine identified by renal biopsy in our 
Hospital.
Management of mesalazine-induced interstitial 
nephritis includes discontinuation of drug and some-
times a trial of corticosteroid therapy. In both cases, 
the history of inflammatory bowel disease, mesala-
zine use and the histopathology, support the diag-
nosis of a drug-associated renal injury.
It is very important to recognize renal impairment 
early, to prevent the progression to an end-stage 
renal disease. We suggest regular monitoring of renal 
function (serum creatinine and urinalysis) in patients 
treated with mesalazine; it is simple, inexpensive 
and it is the only way to diagnose new cases early. 
Further epidemiological data are needed to clarify 
the causal mechanisms of nephrotoxicity. Similar data 
should be reported to estimate the true incidence 
of this serious adverse effect. These cases show us 
the need to create some protocols for routine renal 
function surveillance in IBD patients.
Conflicts of Interest: None declared.
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